RNF43 and metastatic colorectal cancer: A phase I clinical trial of a peptide vaccine ring finger protein 43 (RNF43) and Tomm34 combined with uracil‐tegafur (UFT)/LV for patients with metastatic colorectal cancer has been done in Japan, including the safety and immunological responsiveness of this combination therapy [41].